摘要
目的研究分析不同时机重组人组织型纤溶酶原激活剂(recombinant tissue plasminogen activator,rt-PA)静脉溶栓治疗急性脑梗死伴心房颤动患者的效果。方法选取2019年4月至2020年4月于我院接受治疗的53例急性脑梗死伴心房颤动患者为研究对象,采用随机数字表法分为对照组(n=26)和试验组(n=27),对照组于发病后3.0~4.5 h给予rt-PA静脉溶栓治疗,试验组于发病后3.0 h内给予rt-PA静脉溶栓治疗,比较两组预后情况、治疗前后卒中量表评分、生活质量评分及颅内出血发生情况。结果试验组死亡率低于对照组(P<0.05)。试验组治疗后卒中量表评分低于对照组(P<0.05)。试验组治疗后生活质量评分高于对照组(P<0.05)。试验组各种颅内出血发生情况均低于对照组(P<0.05)。结论相比于发病后3.0~4.5 h,3h内进行rt-PA静脉溶栓治疗急性脑梗死伴心房颤动可有效改善预后,减轻神经功能受损情况,提高患者生活质量并减少颅内出血发生情况。
Objective To study and analyze the effect of intravenous thrombolysis with recombinant tissue plasminogen activator(rt-PA) at different times in patients with acute cerebral infarction and atrial fibrillation. Methods A total of 53 patients with acute cerebral infarction and atrial fibrillation who were treated in our hospital from April 2019 to April 2020 were selected as the study subjects. The patients were divided into control group(n=26) and experimental group(n =27) by random number table method. The control group was given rt-PA intravenous thrombolysis treatment 3.0-4.5 h after onset of disease, and the experimental group was given rt-PA within 3.0 h after onset of disease.Intravenous thrombolysis was used to compare the prognosis, Stroke Scale score before and after treatment, quality of life score and occurrence of intracranial hemorrhage between the two groups. Results The mortality rate in the experimental group was lower than that in the control group(P<0.05).The score of stroke scale in the experimental group was lower than that in the control group after treatment(P<0.05).The quality of life score in the experimental group was higher than that in the control group after treatment(P<0.05).The incidence of intracranial hemorrhage in the experimental group was lower than that in the control group(P< 0.05). Conclusion Compared with 3.0-4.5 h after onset, rt-PA intravenous thrombolysis within 3 h in the treatment of acute cerebral infarction with atrial fibrillation can effectively improve the prognosis, reduce neurological impairment, improve the quality of life of patients and reduce the occurrence of intracranial hemorrhage.
作者
李超强
宁观林
LI Chao-qiang;NING Guan-lin(Department of Geriatrics,Wuchuan People's Hospital,Wuchuan,Guangdong 524500)
出处
《智慧健康》
2021年第17期166-168,共3页
Smart Healthcare
关键词
心房颤动
脑梗死
重组人组织型纤溶酶原激活剂
生活质量
Atrial fibrillation
Cerebral infarction
Recombinant human tissue plasminogen activator
Quality of life
